Last reviewed · How we verify
Anti R-IL2 + Cyclosporine
Anti R-IL2 + Cyclosporine is a Immunosuppressive combination therapy Small molecule drug developed by University Hospital, Brest. It is currently in Phase 3 development for Prevention of acute organ rejection in transplant recipients.
Anti-IL-2 receptor antibody combined with cyclosporine suppresses T-cell activation and proliferation to prevent organ rejection.
Anti-IL-2 receptor antibody combined with cyclosporine suppresses T-cell activation and proliferation to prevent organ rejection. Used for Prevention of acute organ rejection in transplant recipients.
At a glance
| Generic name | Anti R-IL2 + Cyclosporine |
|---|---|
| Sponsor | University Hospital, Brest |
| Drug class | Immunosuppressive combination therapy |
| Target | IL-2 receptor (CD25) and calcineurin |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | Phase 3 |
Mechanism of action
The anti-IL-2 receptor (anti-IL2R) monoclonal antibody blocks the high-affinity IL-2 receptor on activated T lymphocytes, preventing IL-2-driven proliferation. Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription. Together, this combination provides dual immunosuppression targeting different steps of T-cell activation, reducing rejection risk in transplantation.
Approved indications
- Prevention of acute organ rejection in transplant recipients
Common side effects
- Infection
- Nephrotoxicity
- Hypertension
- Hyperglycemia
- Tremor
Key clinical trials
- EVEROLD LONG TERM FOLLOW-UP
- mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti R-IL2 + Cyclosporine CI brief — competitive landscape report
- Anti R-IL2 + Cyclosporine updates RSS · CI watch RSS
- University Hospital, Brest portfolio CI
Frequently asked questions about Anti R-IL2 + Cyclosporine
What is Anti R-IL2 + Cyclosporine?
How does Anti R-IL2 + Cyclosporine work?
What is Anti R-IL2 + Cyclosporine used for?
Who makes Anti R-IL2 + Cyclosporine?
What drug class is Anti R-IL2 + Cyclosporine in?
What development phase is Anti R-IL2 + Cyclosporine in?
What are the side effects of Anti R-IL2 + Cyclosporine?
What does Anti R-IL2 + Cyclosporine target?
Related
- Drug class: All Immunosuppressive combination therapy drugs
- Target: All drugs targeting IL-2 receptor (CD25) and calcineurin
- Manufacturer: University Hospital, Brest — full pipeline
- Therapeutic area: All drugs in Immunology / Transplantation
- Indication: Drugs for Prevention of acute organ rejection in transplant recipients
- Compare: Anti R-IL2 + Cyclosporine vs similar drugs
- Pricing: Anti R-IL2 + Cyclosporine cost, discount & access